
UnicoCell — Investor Relations & Filings
UnicoCell Biomed Co., Ltd. specializes in regenerative medicine, focusing on the research, development, and clinical application of stem cell technologies. The company’s operations are centered on three primary axes: the development of novel stem cell therapeutics, the production of stem cell-derived exosomes, and the provision of cell manufacturing and Contract Development and Manufacturing Organization (CDMO) services. Its lead candidate, ELIXCYTE, is an adipose-derived stem cell therapy undergoing Phase 3 clinical trials for indications such as knee osteoarthritis and chronic kidney disease. Additionally, the company maintains an allogeneic stem cell bank and provides autologous adipose-derived stem cell therapy services. Utilizing patented manufacturing processes and proprietary technology, UnicoCell offers integrated solutions from research to large-scale production to address unmet medical needs in the regenerative therapy sector.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 本公司脂肪幹細胞新藥ELIXCYTE治療膝骨關節炎 (Knee Osteoarthritis)之人體臨床試驗,向衛生福利部 提出申請臨床試驗設計變更。 | 2026-05-29 | Chinese | |
| 功能性委員會成員 | 2026-05-21 | Chinese | |
| 功能性委員會成員 | 2026-05-21 | Chinese | |
| 公告本公司董事會委任薪資報酬委員會委員 | 2026-05-20 | Chinese | |
| 公告本公司審計委員會委員異動 | 2026-05-20 | Chinese | |
| 公告本公司董事會選任董事長 | 2026-05-20 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47889775 | 本公司脂肪幹細胞新藥ELIXCYTE治療膝骨關節炎 (Knee Osteoarthritis)之人體臨床試驗,向衛生福利部 提出申請臨床試驗設計變更。 | 2026-05-29 | Chinese | ||
| 46707409 | 功能性委員會成員 | 2026-05-21 | Chinese | ||
| 46707411 | 功能性委員會成員 | 2026-05-21 | Chinese | ||
| 46586514 | 公告本公司董事會委任薪資報酬委員會委員 | 2026-05-20 | Chinese | ||
| 46586515 | 公告本公司審計委員會委員異動 | 2026-05-20 | Chinese | ||
| 46586516 | 公告本公司董事會選任董事長 | 2026-05-20 | Chinese | ||
| 46586518 | 公告本公司115年股東常會通過解除董事競業禁止之限制 | 2026-05-20 | Chinese | ||
| 46584900 | 公告本公司115年股東常會重要決議事項 | 2026-05-20 | Chinese | ||
| 46584942 | 公告本公司115年股東常會董事改選當選名單(含獨立董事) | 2026-05-20 | Chinese | ||
| 46577281 | 公司治理組織架構 | 2026-05-20 | Chinese | ||
| 45809303 | 115年第1季財務報告書 — 202601_6794_AI2.pdf | 2026-05-12 | Chinese | ||
| 45746236 | 115年第1季權益變動表 | 2026-05-11 | Chinese | ||
| 45741522 | 115年第1季現金流量表 | 2026-05-11 | Chinese | ||
| 45741333 | 115年第1季綜合損益表 | 2026-05-11 | Chinese | ||
| 45740917 | 115年第1季資產負債表 | 2026-05-11 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
HEALIOS K.K.
Clinical-stage biotech developing regenerative medicine and…
|
4593 | JP | Professional, scientific and te… |
|
HeartSciences Inc.
Medical technology company applying AI to electrocardiograp…
|
HSCS | US | Professional, scientific and te… |
|
Heartseed Inc.
Clinical-stage biotech developing regenerative medicine for…
|
219A | JP | Professional, scientific and te… |
|
Hemostemix Inc.
Clinical-stage biotech developing autologous stem cell ther…
|
HEM | CA | Professional, scientific and te… |
|
Herantis Pharma Oyj
A clinical-stage biotech developing therapies for neurodege…
|
HRTIS | FI | Professional, scientific and te… |
|
HEXIMA LIMITED.
Develops plant-derived proteins for human therapeutics and …
|
HXL | AU | Professional, scientific and te… |
|
Hipower Energy Spolka Akcyjna
Develops and commercializes hydrogen-based solutions and fu…
|
HPE | PL | Professional, scientific and te… |
|
HitGen Inc.
Discovers small molecule drug candidates using a DNA-encode…
|
688222 | CN | Professional, scientific and te… |
|
HLB bioStep Co.,Ltd.
A non-clinical CRO providing drug development services, spe…
|
278650 | KR | Professional, scientific and te… |
|
HLB PANAGENE Co., LTD.
Specializes in PNA-based molecular diagnostics for oncology…
|
046210 | KR | Professional, scientific and te… |
UnicoCell via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52633/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52633 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52633 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52633 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52633}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for UnicoCell (id: 52633)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.